ConforMIS, Inc. (CFMS)
(Delayed Data from NSDQ)
$2.66 USD
+0.22 (9.02%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMWe use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$2.66 USD
+0.22 (9.02%)
Updated May 3, 2019 04:00 PM ET
After-Market: $2.65 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGM
Zacks News
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Investors are optimistic about STERIS (STE) backed by elevated consumer demand and strong segmental growth in third-quarter fiscal 2021.
Globus Medical (GMED) Simplifies Spine Surgery With CREO ONE
by Zacks Equity Research
Globus Medical's (GMED) latest development to robotically navigated spine surgery will enable surgeons to maintain the navigational accuracy without performing traditional pedicle preparation.
Walgreens (WBA) Extends COVID-19 Vaccination to 49 States
by Zacks Equity Research
Walgreens (WBA) continues to expand access to COVID-19 vaccination in medically underserved communities and has surpassed 11 million administrations to date.
Here's Why You Should Hold on to STERIS (STE) Stock Now
by Zacks Equity Research
Investors are optimistic about STERIS (STE) owing to strong segmental performance amid the pandemic and huge growth potential in healthcare and pharmaceutical industries.
Abbott (ABT) Gets Europe Nod for TriClip G4 to Treat TR
by Zacks Equity Research
Per Abbott's (ABT) TRILUMINATE CE Mark study, the latest version shows sustained symptomatic improvement, reduction in the severity of TR and improvement in functional status.
Quest Diagnostics (DGX) Rides on Test Sales Amid Volume Woe
by Zacks Equity Research
Quest Diagnostics (DGX) enters into an agreement with the CDC to provide genomic sequencing to identify new mutations in and patterns of transmission of SARS-CoV-2.
Orthofix (OFIX) Wins FDA Clearance for CONSTRUX Mini Ti System
by Zacks Equity Research
Orthofix's (OFIX) CONSTRUX Mini Ti Spacer System, designed with nanoscale surface is the first 3D-printed titanium interbody, was launched to enhance ACDF procedures.
Here's Why You Should Retain Integra LifeSciences (IART) Stock
by Zacks Equity Research
Investors are optimistic about Integra LifeSciences (IART) stock, owing to its strong international business growth and focus on portfolio optimization.
Varian Medical (VAR) Hits 52-Week High: What's Driving It?
by Zacks Equity Research
Varian Medical (VAR) is optimistic about its prospective acquisitions and strength in Proton Therapy segment.
Will Walgreens Boots' (WBA) Retail Arm be Dull in Q2 Earnings?
by Zacks Equity Research
Walgreens Boots' (WBA) Retail Pharmacy International sales are likely to have remained dull in Q2 on difficult global market scenario.
Medtronic (MDT) Directional Lead for DBS System Gets CE Mark
by Zacks Equity Research
This SenSight system according to Medtronic (MDT), is set to enhance detection of local field potentials (LFPs).
Here's Why You Should Add Hologic (HOLX) to Your Portfolio
by Zacks Equity Research
Investors remain optimistic about Hologic (HOLX) on its strong molecular diagnostic growth and robust international performance.
Here's Why You Should Add IDEXX (IDXX) to Your Portfolio Now
by Zacks Equity Research
Investors are optimistic about IDEXX (IDXX) backed by robust CAG and LPD revenues growth and strong global performance boosting the top line.
ConforMIS (CFMS) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
ConforMIS (CFMS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Integra (IART) Neurosurgery Grows Sequentially Amid Supply Woe
by Zacks Equity Research
Most of Integra's (IART) franchises or products succeed in sustaining the momentum after returning to growth in the third quarter.
AngioDynamics (ANGO) at a 52-Week High: What's Driving It?
by Zacks Equity Research
AngioDynamics (ANGO) is optimistic about NanoKnife platform growth and the recent launch of Auryon Atherectomy.
Hologic (HOLX) Partners With Gallup on Women's Health Index
by Zacks Equity Research
Hologic (HOLX) is working to develop a global women's health index through Gallup's World Poll to improve quality of life and life expectancy of women worldwide.
Abbott (ABT) Launches Telehealth Tool for Neuromodulation
by Zacks Equity Research
Abbott (ABT) stated that Medicare will cover remote programming services as a telehealth benefit through the duration of the public health emergency.
QIAGEN (QGEN) Rides on Test Launches Amid COVID-19 Woes
by Zacks Equity Research
QIAGEN (QGEN) expands specimen types that can be used on the existing NeuMoDx SARSCoV-2 test.
ConforMIS (CFMS) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of 27.27% and -0.08%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?
Conformis (CFMS) Looks Good: Stock Adds 7.7% in Session
by Zacks Equity Research
Conformis (CFMS) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.
ConforMIS (CFMS) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of 25.00% and 0.13%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
by Zacks Equity Research
ConforMIS (CFMS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ConforMIS (CFMS) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
ConforMIS (CFMS) delivered earnings and revenue surprises of 76.92% and 32.93%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
ConforMIS (CFMS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
by Zacks Equity Research
ConforMIS (CFMS) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.